Praxis Precision initiated with an Outperform at Oppenheimer

Oppenheimer initiated coverage of Praxis Precision with an Outperform rating and $134 price target. Praxis is a precision central nervous system biotech focused on both prevalent and rare disorders through its two proprietary platforms, the analyst tells investors in a research note. The firm says that despite the risk associated with therapeutics for essential tremor, it believes the company’s “differentiated” trial design gives ulixacaltamide a real shot at success.